| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | CD248; CD164L1; TEM1; Endosialin; Tumor endothelial marker 1; CD248 |
| Entrez GeneID | 57124; |
| WB Predicted band size | 80kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human CD248. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CD248抗体的3篇参考文献及其摘要内容：
1. **文献名称**：*CD248: A Therapeutic Target in Cancer and Fibrotic Diseases*
**作者**：Khan KA, et al.
**摘要**：探讨CD248在肿瘤微环境和纤维化疾病中的表达，证明其抗体通过阻断CD248与细胞外基质的相互作用抑制肿瘤血管生成和纤维化进展。
2. **文献名称**：*Targeting CD248 with Monoclonal Antibodies for Solid Tumor Therapy*
**作者**：Tomkowicz B, et al.
**摘要**：开发了一种靶向CD248的单克隆抗体，体内实验显示其能有效抑制实体瘤生长并增强化疗敏感性，机制涉及抑制内皮细胞迁移和促血管生成信号通路。
3. **文献名称**：*CD248 Antibody Attenuates Inflammation in Experimental Arthritis*
**作者**：Rouleau C, et al.
**摘要**：研究CD248抗体在类风湿性关节炎模型中的作用，发现其通过减少滑膜成纤维细胞活化和炎性细胞浸润显著缓解关节炎症和骨破坏。
这些文献均聚焦于CD248抗体的治疗潜力，覆盖肿瘤、纤维化及炎症性疾病领域。
CD248. also known as TEM1 or endosialin, is a transmembrane glycoprotein belonging to the C-type lectin superfamily. It is predominantly expressed on mesenchymal stromal cells, pericytes, and cancer-associated fibroblasts (CAFs) within the tumor microenvironment. CD248 plays a role in cell adhesion, extracellular matrix remodeling, and angiogenesis, with elevated expression observed during tissue development, injury repair, and pathological conditions like fibrosis and cancer. Its dysregulation is linked to tumor progression, metastasis, and poor prognosis in cancers such as sarcoma, breast cancer, and colorectal carcinoma.
CD248 antibodies are tools developed to detect or modulate CD248 activity. Monoclonal antibodies targeting specific extracellular domains (e.g., FNIII or CTLD regions) enable research applications like immunohistochemistry, flow cytometry, and Western blotting to map CD248 expression patterns. Therapeutically, CD248 antibodies are explored for their potential to inhibit tumor growth by disrupting stromal-tumor interactions, blocking pro-angiogenic signaling, or inducing antibody-dependent cellular cytotoxicity (ADCC). Preclinical studies show that anti-CD248 agents can suppress CAF activity and enhance chemotherapy efficacy. However, clinical translation remains in early phases, with challenges including understanding CD248's dual roles in homeostasis versus disease and optimizing tumor-specific targeting to minimize off-tissue effects. Ongoing research aims to clarify its signaling mechanisms, including interactions with integrins or growth factor receptors, to refine therapeutic strategies.
×
